Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SETD7 | Q8WTS6 | 2/20 | 0.52 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.45 |
| ▸ | SPR | P35270 | 3/20 | 0.44 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.43 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.43 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | ABHD6 | Q9BV23 | 2/20 | 0.41 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31155296 | 0.80 | SETD7 (0.52) | SETD7GPR119SPRSMARCA2SMARCA4 | |
| SCHEMBL1946155 | 0.80 | SETD7 (0.52) | SETD7GPR119SPRSMARCA2SMARCA4 | |
| SCHEMBL1102308 | 0.77 | SETD7 (0.65) | SETD7GPR119SPRHTT | |
| SCHEMBL3638878 | 0.77 | SETD7 (0.65) | SETD7GPR119SPRHTT | |
| SCHEMBL4336794 | 0.76 | SETD7 (0.52) | SETD7SPRSMARCA2SMARCA4PBRM1 | |
| SCHEMBL28055264 | 0.74 | SETD7 (0.51) | SETD7GPR119SPRSMARCA2SMARCA4 | |
| SCHEMBL17560369 | 0.73 | SETD7 (0.50) | SETD7GPR119SPRSMARCA2SMARCA4 | |
| SCHEMBL26666330 | 0.73 | SETD7 (0.50) | SETD7GPR119SPRSMARCA2SMARCA4 | |
| SCHEMBL28060463 | 0.73 | SETD7 (0.50) | SETD7GPR119SPRSMARCA2SMARCA4 | |
| SCHEMBL17560370 | 0.73 | SETD7 (0.50) | SETD7GPR119SPRSMARCA2SMARCA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | SREBF1, SREBF2, NR1H3 | SETD7 4216/4885GPR119 136/4885SPR 1039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.